American Association for Cancer Research
Browse
00085472can211208-sup-264177_2_supp_7218347_qvf8wz.docx (3.58 MB)

Supplemental Text, Supplemental Figures, and Supplemental Tables from Cell Line–Specific Network Models of ER+ Breast Cancer Identify Potential PI3Kα Inhibitor Resistance Mechanisms and Drug Combinations

Download (3.58 MB)
journal contribution
posted on 2023-03-31, 04:42 authored by Jorge Gómez Tejeda Zañudo, Pingping Mao, Clara Alcon, Kailey Kowalski, Gabriela N. Johnson, Guotai Xu, Jose Baselga, Maurizio Scaltriti, Anthony Letai, Joan Montero, Réka Albert, Nikhil Wagle

Word file containing the Supplemental Text, Supplemental Figures S1-S6, and Supplemental Tables S1-S2.

Funding

Ministerio de Economia y Competitividad

NSF

TVF

History

ARTICLE ABSTRACT

Durable control of invasive solid tumors necessitates identifying therapeutic resistance mechanisms and effective drug combinations. In this work, we used a network-based mathematical model to identify sensitivity regulators and drug combinations for the PI3Kα inhibitor alpelisib in estrogen receptor positive (ER+) PIK3CA-mutant breast cancer. The model-predicted efficacious combination of alpelisib and BH3 mimetics, for example, MCL1 inhibitors, was experimentally validated in ER+ breast cancer cell lines. Consistent with the model, FOXO3 downregulation reduced sensitivity to alpelisib, revealing a novel potential resistance mechanism. Cell line–specific sensitivity to combinations of alpelisib and BH3 mimetics depended on which BCL2 family members were highly expressed. On the basis of these results, newly developed cell line–specific network models were able to recapitulate the observed differential response to alpelisib and BH3 mimetics. This approach illustrates how network-based mathematical models can contribute to overcoming the challenge of cancer drug resistance. Network-based mathematical models of oncogenic signaling and experimental validation of its predictions can identify resistance mechanisms for targeted therapies, as this study demonstrates for PI3Kα-specific inhibitors in breast cancer.

Usage metrics

    Cancer Research

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC